SCHEDULE: Scilex Corrects Semnur Ownership Filing, Details Post-Merger Control

Scilex Holding Company filed an amended Schedule 13D for Semnur Pharmaceuticals, Inc. to correct a previous filing error and detail its significant beneficial ownership and control following a recent business combination.

Summary

• This Amendment No. 1 to Schedule 13D was filed by Scilex Holding Company (SHC) and Scilex, Inc. (Reporting Persons) for Semnur Pharmaceuticals, Inc. (Issuer) to correct an incorrect CIK code and Issuer name in the original filing dated September 26, 2025.
• Beneficial ownership figures are presented as of the original filing date, with the number of shares outstanding updated to September 25, 2025.
• SHC and its subsidiaries (Scilex, Inc. and Scilex Bio, Inc.) collectively beneficially own 188,554,849 shares of Common Stock, representing 82.07% of the class.
• Scilex, Inc. beneficially owns 181,804,849 shares, representing 79.13% of the class.
• The aggregate voting power of SHC's holdings, including Common Stock and Series A Preferred Stock, represents 82.49% of the Issuer's total voting power.
• The Issuer consummated a business combination (Merger Agreement) on September 22, 2025, involving Denali Capital Acquisition Corp. (SPAC) and Old Semnur.
• SHC contributed $54,236,058.00 of outstanding indebtedness to Old Semnur, receiving 5,423,606 shares of Series A Preferred Stock of Old Semnur, which were subsequently exchanged for 5,423,606 shares of Series A Preferred Stock and 542,361 shares of Common Stock of the Issuer.
• A convertible promissory note from SPAC to SHC, with $124,883.82 outstanding, converted into 12,488 shares of Common Stock upon the business combination.
• SHC purchased 500,000 SPAC Class B Ordinary Shares for $2,000,000 cash and 300,000 Scilex shares (later settled for $213,932.16 cash), which converted into 500,000 shares of Issuer Common Stock.
• On September 23, 2025, SHC and Scilex, Inc. sold an aggregate of 12,500,000 shares of the Issuer's Common Stock to Biconomy PTE.LTD for a purchase price of $16.00 per share, payable in Bitcoin.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The filing confirms the successful completion of a complex business combination and details Scilex Holding Company's substantial, controlling interest in Semnur Pharmaceuticals. The sale of shares to Biconomy at a specific price also indicates a valuation point. The primary negative is the administrative error in the initial filing, which has been corrected, and the potential for limited independent decision-making due to SHC's extensive control.

Positives

• The successful consummation of the business combination on September 22, 2025, integrates Old Semnur into the Issuer.
• Scilex Holding Company maintains a significant beneficial ownership of 82.07% of Common Stock and 82.49% of total voting power, indicating strong control and strategic alignment.
• The Stockholder Agreement grants SHC substantial governance rights, including board designation and veto power over key corporate actions, ensuring strategic influence.
• The successful sale of 12,500,000 shares to Biconomy PTE.LTD at $16.00 per share provides liquidity for the sellers and potentially validates a valuation point for the Issuer's stock.

Negatives

• The initial Schedule 13D filing contained an incorrect CIK code and Issuer name, requiring an amendment, which could indicate administrative oversight.
• SHC and Scilex, Inc. transferred an aggregate of 12,500,000 shares of the Issuer's Common Stock to a third party, reducing their direct holdings, although this was a strategic sale.

Risks

• Governance Concentration: Scilex Holding Company's significant beneficial ownership and the Stockholder Agreement's provisions grant it substantial control over the Issuer's board and key corporate actions, potentially limiting minority shareholder influence and independent decision-making.
• Integration Risks: While the business combination is complete, the filing does not detail potential challenges in integrating Old Semnur's operations, personnel, or technologies, which could impact future performance.
• Market Volatility: The sale of shares to Biconomy PTE.LTD was for Bitcoin, introducing cryptocurrency market volatility risk for the proceeds received by the Scilex Sellers.
• Regulatory Scrutiny: The initial filing error (incorrect CIK code) could draw minor regulatory attention, though it has been corrected.

Future Outlook

The filing primarily details past transactions and current ownership structure. It does not provide explicit forward-looking statements or guidance regarding future financial performance, operational plans, or market expectations for Semnur Pharmaceuticals, Inc.

Management Comments

• Reporting Persons are correcting a previous filing error related to the Issuer's CIK code and name, which was recently discovered.

Industry Context

The filing describes a business combination involving a SPAC, which is a common mechanism for private companies to go public. The subsequent sale of shares to a third party, Biconomy PTE.LTD, for Bitcoin, indicates an engagement with digital asset transactions, which is an emerging trend in corporate finance, particularly for companies in innovative sectors. The significant control retained by Scilex Holding Company suggests a strategic consolidation within the pharmaceutical or biotechnology sector, where larger entities often acquire or merge with smaller, specialized firms.

Comparison to Industry Standards

• The use of a SPAC for the business combination aligns with a prevalent trend in recent years for private companies to access public markets, though the SPAC market has seen fluctuations.
• The sale of shares for Bitcoin to Biconomy PTE.LTD is an unconventional payment method in traditional M&A or equity transactions, indicating a willingness to engage with digital assets, which is not yet a widespread industry standard but is gaining traction in certain tech-forward sectors.
• Scilex Holding Company's beneficial ownership of over 82% post-merger is a very high level of control, typical of a parent company consolidating a subsidiary rather than a typical public float, and grants it significant influence over corporate governance, which is higher than average for publicly traded companies where a more diversified shareholder base is common.

Corporate Governance

Related Party Transactions

• Business Combination between SPAC (Denali Capital Acquisition Corp.) and Old Semnur, where Old Semnur was a wholly owned, indirect subsidiary of SHC.
• Debt Exchange Agreement between SHC and Old Semnur, where SHC contributed $54,236,058.00 of debt to Old Semnur in exchange for Series A Preferred Stock.
• Convertible Promissory Note issued by SPAC to SHC.
• Sponsor Interest Purchase Agreement between SPAC's sponsor and SHC.
• Securities Purchase Agreement (Biconomy Resale SPA) between Scilex Sellers (SHC and Scilex, Inc.) and Biconomy PTE.LTD, where Scilex Sellers sold 12,500,000 shares of Issuer's Common Stock.

Stakeholder Impact

• Shareholders (Scilex Holding Company): Maintains significant control and beneficial ownership (82.07% of Common Stock, 82.49% of voting power), ensuring strategic influence and potential for long-term value creation from Semnur.
• Minority Shareholders (Semnur Pharmaceuticals): Their influence on corporate decisions may be significantly limited due to SHC's extensive control rights outlined in the Stockholder Agreement.
• Management (Semnur Pharmaceuticals): Operational and strategic decisions will be subject to SHC's oversight and consent for key actions, as per the Stockholder Agreement.
• Creditors (Semnur Pharmaceuticals): The $10,000,000 limit on incurring new indebtedness without SHC's consent provides a layer of financial control, potentially impacting future financing flexibility.

Next Steps

• The Issuer will continue to operate under the governance structure established by the Stockholder Agreement, with SHC having significant influence.
• The Registration Rights Agreement will govern the future registration and resale of certain shares of Issuer Common Stock for certain security holders.

Key Dates

Recommendation

The filing confirms the successful completion of the business combination and details Scilex Holding Company's substantial, controlling interest in Semnur Pharmaceuticals, Inc., including significant governance rights. It also discloses a recent large share sale to Biconomy PTE.LTD at $16.00 per share. While the strong control by SHC provides stability and strategic alignment, the filing does not offer new operational or financial performance metrics for Semnur that would fundamentally alter its investment thesis. The correction of a previous administrative error is a positive for transparency but not a driver for a change in investment stance. Therefore, a 'hold' recommendation is appropriate as investors should await further operational and financial updates from Semnur to reassess its intrinsic value and growth prospects.

Keywords

Semnur Pharmaceuticals, Scilex Holding Company, Schedule 13D, Business Combination, Merger, Beneficial Ownership, Corporate Governance, Stockholder Agreement, SPAC, Denali Capital Acquisition Corp., Biconomy PTE.LTD, Common Stock, Series A Preferred Stock, Debt Exchange, Convertible Note, Share Sale, Biotechnology, Pharmaceuticals